Kite, Juno gain on CAR T data at ASCO

Juno Therapeutics Inc. (NASDAQ:JUNO) and Kite Pharma Inc. (NASDAQ:KITE) each posted gains Monday after presenting updated data for their respective chimeric antigen receptor T cell therapies targeting CD19 at the American Society of Clinical Oncology meeting. Both companies hope to seek accelerated approvals of their lead programs by next year.

Juno climbed $4.60 (10%) to $48.50 after presenting data for clinical CAR T candidates including JCAR015, its most advanced program. ...